CA3065852A1 - Antibody conjugates of immune-modulatory compounds and uses thereof - Google Patents
Antibody conjugates of immune-modulatory compounds and uses thereof Download PDFInfo
- Publication number
- CA3065852A1 CA3065852A1 CA3065852A CA3065852A CA3065852A1 CA 3065852 A1 CA3065852 A1 CA 3065852A1 CA 3065852 A CA3065852 A CA 3065852A CA 3065852 A CA3065852 A CA 3065852A CA 3065852 A1 CA3065852 A1 CA 3065852A1
- Authority
- CA
- Canada
- Prior art keywords
- seq
- amino acid
- acid sequence
- sequence
- identity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6845—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a cytokine, e.g. growth factors, VEGF, TNF, a lymphokine or an interferon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762516638P | 2017-06-07 | 2017-06-07 | |
| US62/516,638 | 2017-06-07 | ||
| PCT/US2018/036554 WO2018227018A1 (en) | 2017-06-07 | 2018-06-07 | Antibody conjugates of immune-modulatory compounds and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3065852A1 true CA3065852A1 (en) | 2018-12-13 |
Family
ID=64567206
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3065852A Abandoned CA3065852A1 (en) | 2017-06-07 | 2018-06-07 | Antibody conjugates of immune-modulatory compounds and uses thereof |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20200199247A1 (cg-RX-API-DMAC10.html) |
| EP (1) | EP3634485A4 (cg-RX-API-DMAC10.html) |
| JP (1) | JP2020523319A (cg-RX-API-DMAC10.html) |
| CN (1) | CN110891605A (cg-RX-API-DMAC10.html) |
| AU (1) | AU2018279105A1 (cg-RX-API-DMAC10.html) |
| CA (1) | CA3065852A1 (cg-RX-API-DMAC10.html) |
| WO (1) | WO2018227018A1 (cg-RX-API-DMAC10.html) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4157883A4 (en) * | 2020-06-02 | 2024-12-04 | Children's Medical Center Corporation | NANOBODY CONJUGATES (VHH) AND THEIR USES |
Families Citing this family (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11583593B2 (en) | 2016-01-14 | 2023-02-21 | Synthis Therapeutics, Inc. | Antibody-ALK5 inhibitor conjugates and their uses |
| BR112019000071A2 (pt) | 2016-07-07 | 2019-07-02 | Bolt Biotherapeutics Inc | conjugados adjuvantes de anticorpo |
| AU2018273914A1 (en) | 2017-05-24 | 2019-11-14 | Pandion Operations, Inc. | Targeted immunotolerance |
| US10946068B2 (en) | 2017-12-06 | 2021-03-16 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| US10174091B1 (en) | 2017-12-06 | 2019-01-08 | Pandion Therapeutics, Inc. | IL-2 muteins |
| BR112020023926A2 (pt) * | 2018-05-25 | 2021-02-17 | Silverback Therapeutics, Inc. | compostos de amino-pirazinocarboxamida, conjugados e usos dos mesmos |
| CN111018857B (zh) * | 2018-10-09 | 2023-06-02 | 嘉兴优博生物技术有限公司 | 靶向蛋白酶降解平台(ted) |
| UA128431C2 (uk) | 2018-11-26 | 2024-07-10 | Форті Севен, Інк. | ГУМАНІЗОВАНЕ АНТИТІЛО ДО c-Kit |
| EP3937984A1 (en) | 2019-03-15 | 2022-01-19 | Bolt Biotherapeutics, Inc. | Immunoconjugates targeting her2 |
| EP3725370A1 (en) | 2019-04-19 | 2020-10-21 | ImmunoBrain Checkpoint, Inc. | Modified anti-pd-l1 antibodies and methods and uses for treating a neurodegenerative disease |
| CA3139274A1 (en) * | 2019-05-10 | 2020-11-19 | Lyvgen Biopharma Co., Ltd. | Humanized anti-cd137 antibodies and uses thereof |
| AU2020279240A1 (en) | 2019-05-20 | 2021-12-23 | Pandion Operations, Inc. | MAdCAM targeted immunotolerance |
| EP3999544A4 (en) * | 2019-07-19 | 2023-08-09 | Wuxi Xdc Singapore Private Limited | POLYPEPTIDE COMPLEX FOR CONJUGATION AND ITS USE |
| EP4008730A4 (en) * | 2019-08-02 | 2023-09-06 | Akeso Pharmaceuticals, Inc. | BISPECIFIC ANTI-CTLA4-ANTI-PD-1 ANTIBODY AND ITS USES |
| WO2021102332A1 (en) * | 2019-11-22 | 2021-05-27 | Silverback Therapeutics, Inc. | Tgfbetar2 inhibitor-lrrc15 antibody conjugates and uses thereof |
| EP4041769A1 (en) * | 2019-12-12 | 2022-08-17 | The United States of America, as represented by the Secretary, Department of Health and Human Services | Antibody-drug conjugates specific for cd276 and uses thereof |
| CN115052663B (zh) * | 2020-01-08 | 2026-06-09 | 辛瑟斯治疗股份有限公司 | Alk5抑制剂缀合物及其用途 |
| TWI854088B (zh) * | 2020-01-27 | 2024-09-01 | 英商梅迪繆思有限公司 | 用於治療腎臟疾病之抗αvβ8整聯蛋白抗體 |
| US11981715B2 (en) | 2020-02-21 | 2024-05-14 | Pandion Operations, Inc. | Tissue targeted immunotolerance with a CD39 effector |
| US11179473B2 (en) | 2020-02-21 | 2021-11-23 | Silverback Therapeutics, Inc. | Nectin-4 antibody conjugates and uses thereof |
| CN115379848A (zh) * | 2020-04-01 | 2022-11-22 | 加利福尼亚大学董事会 | 靶向间充质干细胞衍生的癌细胞和间充质干细胞相关疾病的免疫治疗诊断剂 |
| CN113509557A (zh) * | 2020-04-09 | 2021-10-19 | 嘉兴优博生物技术有限公司 | 靶向蛋白酶降解平台(ted) |
| WO2021231922A1 (en) * | 2020-05-14 | 2021-11-18 | The General Hospital Corporation | Agonistic tumor necrosis factor receptor superfamily polypeptides |
| WO2021243136A2 (en) * | 2020-05-29 | 2021-12-02 | New York Society For The Relief Of The Ruptured And Crippled, Maintaining The Hospital For Special Surgery | Methods and compositions for treating, preventing the onset and/or slowing progression of osteoarthritis |
| CN117083079A (zh) * | 2020-06-02 | 2023-11-17 | 儿童医学中心公司 | 纳米抗体(vhh)缀合物及其用途 |
| KR20230047361A (ko) | 2020-07-01 | 2023-04-07 | 아르스 파마슈티컬스 인크. | 항-asgr1 항체 접합체 및 이의 용도 |
| KR102506295B1 (ko) * | 2020-08-28 | 2023-03-08 | 국립암센터 | 디그옥시제닌에 대한 인간화 항체 및 이의 용도 |
| CN114146095A (zh) * | 2020-09-07 | 2022-03-08 | 是光隽恒(北京)生物科技有限公司 | 用于组织损伤修复的组合物及其制备方法和用途 |
| WO2022053864A1 (en) * | 2020-09-08 | 2022-03-17 | Kwon Byoung S | Pd-1 polypeptide variants |
| GB202104935D0 (en) * | 2021-04-07 | 2021-05-19 | Hummingbird Bioscience Holdings Pte Ltd | BCMA/TACI antigen-binding molecules |
| WO2022109105A1 (en) * | 2020-11-18 | 2022-05-27 | Pandion Operations, Inc. | Madcam targeted therapeutics and uses thereof |
| AU2022254042A1 (en) * | 2021-04-07 | 2023-09-14 | Mythic Therapeutics, Inc. | Antigen-binding protein constructs and antibodies and uses thereof |
| WO2022217022A1 (en) | 2021-04-10 | 2022-10-13 | Profoundbio Us Co. | Folr1 binding agents, conjugates thereof and methods of using the same |
| CA3216459A1 (en) | 2021-04-23 | 2022-10-27 | Profoundbio Us Co. | Anti-cd70 antibodies, conjugates thereof and methods of using the same |
| JP2024526259A (ja) | 2021-07-02 | 2024-07-17 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | 抗protac抗体および複合体 |
| TW202320857A (zh) | 2021-07-06 | 2023-06-01 | 美商普方生物製藥美國公司 | 連接子、藥物連接子及其結合物及其使用方法 |
| US20250043005A1 (en) * | 2021-12-09 | 2025-02-06 | Genequantum Healthcare (Suzhou) Co., Ltd. | Antibody-cytokine fusion proteins and applications thereof |
| EP4458830A4 (en) * | 2021-12-30 | 2025-12-03 | Sichuan Kelun Biotech Biopharmaceutical Co Ltd | TRICYCLIC COMPOUND, ITS PREPARATION PROCESS AND ITS USE |
| CA3262796A1 (en) * | 2022-09-20 | 2024-03-28 | Currus Biologics Pty Ltd | Bispecific Polypeptides and Their Uses |
| CN120417934A (zh) * | 2022-12-23 | 2025-08-01 | 基因泰克公司 | Cereblon降解剂缀合物及其用途 |
| IL321713A (en) | 2022-12-27 | 2025-08-01 | Merck Patent Gmbh | Anti-PROTAC VHH antibodies and complexes |
| WO2024200987A1 (en) * | 2023-03-31 | 2024-10-03 | Avacta Life Sciences Limited | Tnfr2 binding polypeptides and methods of use |
| FR3147278A1 (fr) * | 2023-03-31 | 2024-10-04 | Avacta Life Sciences Limited | Polypeptides de liaison au tnfr2 et procedes d'utilisation |
| FR3147292A1 (fr) * | 2023-03-31 | 2024-10-04 | Affyxell Therapeutics Co., Ltd. | Cellules genetiquement modifiees dans lesquelles un acide nucleique codant pour des variantes de la proteine stefine a se liant specifiquement au tnfr2 ou une proteine de fusion comprenant celle-ci a ete introduite, et leurs utilisations |
| KR20260023524A (ko) * | 2023-05-18 | 2026-02-20 | 파이어플라이 바이오, 인크. | 이소인돌리논-글루타르이미드 항체 접합체 및 이의 용도 |
| WO2024243545A1 (en) * | 2023-05-24 | 2024-11-28 | President And Fellows Of Harvard College | Compositions targeting endothelial cells and uses thereof |
| AR133955A1 (es) | 2023-09-26 | 2025-11-19 | Profoundbio Us Co | Agentes de unión a ptk7, conjugados de éstos y métodos de uso de los mismos |
| TW202547866A (zh) | 2024-01-10 | 2025-12-16 | 丹麥商珍美寶股份有限公司 | Slitrk6結合劑、其共軛物及使用彼之方法 |
| WO2025163120A1 (en) * | 2024-02-01 | 2025-08-07 | Adcytherix Sas | ANTIBODY-DRUG CONJUGATES COMPRISING AN ANTI-INTEGRIN ΑVβ6 BINDING ANTIBODY |
| EP4595981A1 (en) * | 2024-02-01 | 2025-08-06 | Jack Elands | Antibody-drug conjugates comprising an anti-integrin v 6 binding antibody |
| WO2025181219A1 (en) | 2024-02-29 | 2025-09-04 | Genmab A/S | Egfr and c-met bispecific binding agents, conjugates thereof and methods of using the same |
| WO2025216667A1 (en) * | 2024-04-12 | 2025-10-16 | Joint Stock Company «Biocad» | Monoclonal antibody that specifically binds to bdca-2 |
| WO2026093513A1 (en) | 2024-10-31 | 2026-05-07 | Sotio Biotech A.S. | Anti-lrrc15 antibodies and uses thereof |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TR201808537T4 (tr) * | 2004-09-23 | 2018-07-23 | Genentech Inc | Sistein değiştirilmiş antikorlar ve konjugatlar. |
| KR101281501B1 (ko) * | 2004-12-09 | 2013-07-15 | 얀센 바이오테크 인코포레이티드 | 항인테그린 면역 컨쥬게이트, 방법 및 용도 |
| WO2011040973A2 (en) * | 2009-10-02 | 2011-04-07 | Ludwig Institute For Cancer Research Ltd. | Tnf-immunoconjugates with fibroblast activation protein antibodies and methods and uses thereof |
| WO2011040972A1 (en) * | 2009-10-02 | 2011-04-07 | Ludwig Institute For Cancer Research Ltd. | Anti-fibroblast activation protein antibodies and methods and uses thereof |
| EP2608804A4 (en) * | 2010-08-27 | 2015-03-11 | Univ Miami | TREATMENT OF KIDNEY DISEASES |
| EA201892619A1 (ru) * | 2011-04-29 | 2019-04-30 | Роше Гликарт Аг | Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2 |
| KR102438072B1 (ko) * | 2012-01-12 | 2022-08-31 | 예일 유니버시티 | E3 유비퀴틴 리가아제에 의한 표적 단백질 및 다른 폴리펩티드의 증진된 분해를 위한 화합물 및 방법 |
| CN104053513B (zh) * | 2012-01-26 | 2016-05-11 | 株式会社万 | 弯曲中空管的制造方法 |
| DK3151865T3 (da) * | 2014-05-22 | 2021-10-25 | Byondis Bv | Stedsspecifik konjugation af linker medicin til antistof og resulterende adcs |
| AR105654A1 (es) * | 2015-08-24 | 2017-10-25 | Lilly Co Eli | Anticuerpos pd-l1 (ligando 1 de muerte celular programada) |
| EP3383909B1 (en) * | 2015-11-30 | 2020-06-17 | AbbVie Inc. | Anti-human lrrc15 antibody drug conjugates and methods for their use |
| JP2019501124A (ja) * | 2015-11-30 | 2019-01-17 | アッヴィ・インコーポレイテッド | 抗huLRRC15抗体薬物コンジュゲート及びその使用方法 |
| US20210154188A1 (en) * | 2018-04-02 | 2021-05-27 | Silverback Therapeutics, Inc. | Alk5 inhibitors, conjugates, and uses thereof |
| BR112020023926A2 (pt) * | 2018-05-25 | 2021-02-17 | Silverback Therapeutics, Inc. | compostos de amino-pirazinocarboxamida, conjugados e usos dos mesmos |
-
2018
- 2018-06-07 US US16/620,429 patent/US20200199247A1/en not_active Abandoned
- 2018-06-07 CN CN201880047508.3A patent/CN110891605A/zh active Pending
- 2018-06-07 WO PCT/US2018/036554 patent/WO2018227018A1/en not_active Ceased
- 2018-06-07 CA CA3065852A patent/CA3065852A1/en not_active Abandoned
- 2018-06-07 AU AU2018279105A patent/AU2018279105A1/en not_active Abandoned
- 2018-06-07 EP EP18813505.7A patent/EP3634485A4/en not_active Withdrawn
- 2018-06-07 JP JP2019567691A patent/JP2020523319A/ja active Pending
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4157883A4 (en) * | 2020-06-02 | 2024-12-04 | Children's Medical Center Corporation | NANOBODY CONJUGATES (VHH) AND THEIR USES |
Also Published As
| Publication number | Publication date |
|---|---|
| CN110891605A (zh) | 2020-03-17 |
| WO2018227018A1 (en) | 2018-12-13 |
| AU2018279105A1 (en) | 2019-12-19 |
| EP3634485A4 (en) | 2021-07-21 |
| JP2020523319A (ja) | 2020-08-06 |
| US20200199247A1 (en) | 2020-06-25 |
| EP3634485A1 (en) | 2020-04-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20200199247A1 (en) | Antibody conjugates of immune-modulatory compounds and uses thereof | |
| EP3595668B1 (en) | Benzazepine compounds, conjugates, and uses thereof | |
| US20220362396A1 (en) | Amino-pyrazinecarboxamide compounds, conjugates, and uses thereof | |
| WO2018227023A1 (en) | Antibody construct conjugates | |
| CA3112545A1 (en) | Substituted benzazepine compounds, conjugates, and uses thereof | |
| CA3146661A1 (en) | Alk5 inhibitors, conjugates, and uses thereof | |
| CA3049791A1 (en) | Tumor targeting conjugates and methods of use thereof | |
| AU2018385693A1 (en) | Antibody construct-drug conjugate for the treatment of hepatitis | |
| EP3386536A2 (en) | Composition of antibody construct-agonist conjugates and methods of use thereof | |
| CA3131104A1 (en) | Cyclic amino-pyrazinecarboxamide compounds and uses thereof | |
| KR20210061995A (ko) | Adam9를 표적으로 하는 면역콘쥬게이트 및 이를 이용하는 방법들 | |
| AU2020358726A1 (en) | Combination therapy with immune stimulatory conjugates | |
| WO2022006340A1 (en) | Alk5 inhibitors, conjugates, and uses thereof | |
| WO2022076905A1 (en) | Alk5 inhibitors, conjugates, and uses thereof | |
| RU2780334C2 (ru) | Бензазепиновые соединения, конъюгаты и их применение | |
| GB2552041A (en) | Compositions of antibody construct-agonist conjugates and methods thereof | |
| HK40021778A (en) | Benzazepine compounds, conjugates, and uses thereof | |
| HK40021778B (en) | Benzazepine compounds, conjugates, and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |
Effective date: 20231207 |